Mirum Pharmaceuticals, Inc. (MIRM)
97.18
+1.68
(+1.75%)
USD |
NASDAQ |
Nov 20, 10:10
Mirum Pharmaceuticals Cash from Operations (Quarterly) : -4.311M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -4.311M |
| June 30, 2026 | -44.25M |
| March 31, 2026 | -228.76M |
| December 31, 2025 | 6.067M |
| September 30, 2025 | 39.68M |
| June 30, 2025 | 12.04M |
| March 31, 2025 | -1.961M |
| December 31, 2024 | -5.068M |
| September 30, 2024 | 3.984M |
| June 30, 2024 | -3.803M |
| March 31, 2024 | 15.21M |
| December 31, 2023 | -16.62M |
| September 30, 2023 | -18.22M |
| June 30, 2023 | -2.331M |
| March 31, 2023 | -33.77M |
| December 31, 2022 | -34.27M |
| Date | Value |
|---|---|
| September 30, 2022 | -26.02M |
| June 30, 2022 | -20.17M |
| March 31, 2022 | -39.67M |
| December 31, 2021 | -33.15M |
| September 30, 2021 | -34.20M |
| June 30, 2021 | -40.20M |
| March 31, 2021 | -25.21M |
| December 31, 2020 | -36.28M |
| September 30, 2020 | -17.45M |
| June 30, 2020 | -16.99M |
| March 31, 2020 | -18.35M |
| December 31, 2019 | -13.70M |
| September 30, 2019 | -15.22M |
| June 30, 2019 | -8.017M |
| March 31, 2019 | -2.426M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Incyte Corp. | -675.32M |
| Galectin Therapeutics, Inc. | -2.265M |
| TG Therapeutics, Inc. | 45.23M |
| Ardelyx, Inc. | 2.171M |
| Kodiak Sciences, Inc. | -43.86M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -28.87M |
| Cash from Financing (Quarterly) | -54.34M |
| Free Cash Flow | -308.85M |
| Free Cash Flow Per Share (Quarterly) | -0.0857 |
| Free Cash Flow to Equity (Quarterly) | 13.77M |
| Free Cash Flow to Firm (Quarterly) | -3.988M |
| Free Cash Flow Yield | -4.87% |